5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) StockDefense World · Sep 20, 2026
Andrew Schwab Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) StockDefense World · Sep 20, 2026
Skye Bioscience to Merge With Redx, Forming Fibrosis-Focused Fibrx TherapeuticsDefense World · Aug 19, 2026
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks TranscriptSeeking Alpha · Aug 14, 2026
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in FinancingsGlobeNewsWire · Aug 14, 2026
Skye Bioscience (NASDAQ:SKYE) Trading 2.8% Higher – Time to Buy?Defense World · Aug 4, 2026Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$2.04 | -$2.16 | Miss |
| May 11, 2026 | -$0.29 | -$0.32 | Miss |
| Mar 19, 2026 | -$2.32 | -$2.88 | Miss |
| Nov 10, 2025 | -$2.64 | -$2.56 | Beat |
| Aug 8, 2025 | -$2.72 | -$0.44 | Beat |
| May 8, 2025 | -$2.48 | -$0.28 | Beat |